Table 4 Review of series concerning NSS/PN for > 7 cm tumors
|  | Tumors(n) | Surgical approach | Tumor size (cm) | Tumor size range (cm) | Median follow-up (months) | Positive margins, n (%) | Major Complication(CDS > 3), n(%) | preoperative renal function | postoperative Renal function |
|---|---|---|---|---|---|---|---|---|---|
Present study(2024) | 28 | R-PN: 28 | 9.90(mean) | 7.2 ~ 19 | 47.5 | 0(0) | 3(10.71) | (mean) eGFR:81.2 mL/min | (mean) - 6.68 mL/min |
de Saint Aubert(2018)[13] | 49 | Open:48 LPN:1 | 8.6(mean) | NA | 31 | 2(10.5) | 8(16) | (mean) eGFR:76.9 mL/min | (mean) eGFR:68.9 mL/min |
Rouffilange(2018) [25] | 37 | Open:34 T-PN:3 | 8 (median) | NA | 31 | NA | 3(8.1) | (median) eGFR:80 mL/min | (median) eGFR:77 mL/min |
Tsivian(2017) [22] | 27 | T-PN:27 | 8(median) | 7 ~ 15 | NA | 1(3.7) | 3(11.1) | NA | NA |
Bigot(2014) [26] | 168 | Open:154 LPN:11 RAPN:3 | 8 (median) | 7 ~ 18 | 30 | 14 (10.9) | 33(19.6) | (mean) eGFR: 75.3mL/min | (mean) eGFR: 67.66 ml/min |
Long(2012) [27] | 49 | RAPN:5 | 8.7(median) | 7 ~ 30 | 13.1 | 5 (10.2) | 6(12.2) | (median) Cr: 1.18 mg/dL | (median) Cr: 1.30 mg/dL |
Becker(2011)[28] | 91 | Open: 90 T-PN:1 | 8(median) | 7 ~ 17 | 28 | NA | 10(10.9) | median) eGFR:92.1 mL/min | (median) eGFR:81 mL/min |
Karellas(2010) [29] | 37 | Open:32 LPN:5 | 7.5(median) | 7–19 | 17 | 0 | 4(11) | (median) eGFR:65 mL/min | (median) eGFR:55 mL/min |
Breau(2010) [14] | 57 | NA | 7.5(median) | NA | 38 | NA | 14(20.2) | (median) Cr.: 1.2 mg/dL | (median)  + 9.5% |
Jeldres(2009) [30] | 29 | NA | 8.5(median) | NA | 54 | NA | NA | NA | NA |
Hafez(1999) [2] | 50 | Open | 9.9(median) | NA | 47 | NA | NA | NA | NA |